SCHEMBL13993304

SCHEMBL13993304

CC(F)(F)C(C)(NC(=O)N1CCOCC1)C(C)(F)F

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.49
SMN1; SMN2 Q16637 5/20 0.47
PKM P14618 1/20 0.47
USP2 O75604 1/20 0.43
MLYCD O95822 1/20 0.43
CTSS P25774 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10122263 0.89 HTT (0.49) HTTSMN1; SMN2PKMUSP2MLYCD
SCHEMBL823974 0.81 HTT (0.55) HTTSMN1; SMN2PKMUSP2CTSS
SCHEMBL13993504 0.76 GAA (0.45) HTTSMN1; SMN2GAANPC1RAB9A
SCHEMBL10123383 0.75 GAA (0.44) HTTSMN1; SMN2CYP2C19ALDH1A1GAA
SCHEMBL10123579 0.75 GAA (0.44) HTTSMN1; SMN2CYP2C19ALDH1A1GAA
SCHEMBL11032606 0.74 HTT (0.51) HTTSMN1; SMN2PKMUSP2CTSS
SCHEMBL8909399 0.72 HTT (0.50) HTTSMN1; SMN2PKMUSP2CTSS
SCHEMBL10122411 0.72 GAA (0.47) HTTSMN1; SMN2GAANPC1RAB9A
SCHEMBL27672077 0.71 HTT (0.49) HTTSMN1; SMN2PKMMLYCDCTSS
SCHEMBL10123504 0.71 LMNA (0.45) SMN1; SMN2CYP2C9CYP2C19ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147474-A2 SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2008-12-04 WO disclosed